We could not find any results for:
Make sure your spelling is correct or try broadening your search.
MINDBIO THERAPEUTICS BEGINS DOSING MB22001 IN PHASE 2 CLINICAL TRIAL IN WORLD FIRST TAKE-HOME MICRODOSING STUDY IN PATIENTS WITH DEPRESSION World-first take-home approvals...
MINDBIO THERAPEUTICS BREAKTHROUGH DISCOVERY IN MICRODOSING CLINICAL TRIAL REVEALS SIGNIFICANT POSITIVE EFFECTS ON QUALITY OF SLEEPNew Discovery: MindBio's LSD-Microdosing Treatment Improves...
MINDBIO THERAPEUTICS CEO DEMONSTRATES HOW 1 MILLION MICRODOSES OF LSD CAN POTENTIALLY BE USED TO TREAT DEPRESSION 1 Million Microdoses used to create proprietary microdosing...
ETHICS APPROVAL FOR LANDMARK WORLD FIRST PHASE 2 CLINICAL TRIAL OF TAKE-HOME LSD-MICRODOSING FOR MAJOR DEPRESSIVE DISORDEREthics approval received for take-home LSD-Microdosing clinical...
PHASE 2 CLINICAL TRIAL HAS RECEIVED ETHICS APPROVAL FOR WORLD FIRST TAKE-HOME LSD-MICRODOSING TRIALS IN CANCER PATIENTS EXPERIENCING EMOTIONAL DISTRESSEthics approval granted The clinical trial...
MindBio Therapeutics Corp (CSE: MBIO) Reveals Scientific Paper in World-First Take-Home, LSD-Microdosing Clinical Trial in 80 Healthy Participants MindBio clinical trial...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.005 | -8.33333333333 | 0.06 | 0.06 | 0.055 | 41942 | 0.05531362 | CS |
4 | 0.005 | 10 | 0.05 | 0.065 | 0.045 | 75542 | 0.05629901 | CS |
12 | 0.03 | 120 | 0.025 | 0.085 | 0.025 | 72555 | 0.05747383 | CS |
26 | 0.025 | 83.3333333333 | 0.03 | 0.085 | 0.015 | 56910 | 0.04627647 | CS |
52 | -0.505 | -90.1785714286 | 0.56 | 0.56 | 0.015 | 76251 | 0.07094801 | CS |
156 | -0.505 | -90.1785714286 | 0.56 | 0.56 | 0.015 | 76251 | 0.07094801 | CS |
260 | -0.505 | -90.1785714286 | 0.56 | 0.56 | 0.015 | 76251 | 0.07094801 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions